scm logo

The company was invited to the world-renowned stem cell conference 2015 (Stem Cell Meeting on the Mesa 2015) and announced the results of stem cell therapy research. 

The event will be held in San Diego, the U.S. for three days from the 7th, with many world-class multinational pharmaceutical companies, companies, investment companies, research institutes, government agencies, medical charities and patient rights organizations participating.

The Alliance for Regenerative Medicine (ARM), which is the organizer of the event and has the highest authority in the field of regenerative medicine, invited only 63 bio-pharmaceutical companies, including us, to hold the event.

The invited companies discussed copyright alliance and attracting investment to the world's top multinational pharmaceutical companies and venture investment companies.

The company, which was invited for the first time this time, held patents from South Korea, the United States, Japan, China, and the European Union for the "SCM, Subfraction Culturing Method" that can separate high-purity adult stem cells (CMCs).

The "“Subfractionation Culturing Method”" is a technology that separates high-purity stem cells with much higher purity than the existing stem cell separation method, the "agricultural drainage centrifugation method."

At this event, our CEO Song Sun-uk announced the results of the research process over the past eight years, the background of effective stem cell treatment development, and solutions for commercialization on the morning of the 8th, the second day of the event.

Song Soon-Uk, CEO of our company, said, "I am happy to announce the achievements I have been making so far by being invited to the world-renowned stem cell conference," adding, "We hope that the self-developed high-purity stem cell separation and culture technologies and treatments will be silently researched and developed for the completeness of the technology without premature commercialization," he said.

The company secured original technologies, patents, and manufacturing facilities for stem cell treatments for intractable diseases and started as Hanjin Group affiliate "Homiocerapy" in 2008 and celebrated its 7th anniversary last year. In March, it was evaluated as a company with advanced technology that can open a new chapter in stem cell treatment while attracting a total of 7 billion won from domestic venture capital.